Skip to main content
    N

    Nuvectis Pharma Inc (NVCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.11
    -1.13 (-5.58%)

    Market Cap: $696.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Nuvectis Pharma Inc (NVCT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Nuvectis Pharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$26.44M, operating cash flow was -$16.01M and free cash flow was -$16.01M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$30.07M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $27.57M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$18.15M$12.92M$15.38M$13.23M$9.54M$0
    Operating income-$27.57M-$19.85M-$22.90M-$19.23M-$12.89M-$10.00K
    Net income-$26.44M-$19.00M-$22.26M-$19.09M-$12.89M-$10.00K
    EBITDA-$27.57M-$19.00M-$22.26M-$19.09M-$12.89M-$10.00K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$26.80M$0$0$0-$4.10M
    Gross profit$0$0$0N/A$0$0$0$13.40M$0$0$0-$15.07M
    Operating income-$31.05M-$7.20M-$6.26M-$7.62M-$7.79M-$6.59M-$5.57M-$6.45M-$4.36M-$4.64M-$4.40M-$6.87M
    Net income-$30.07M-$7.02M-$6.05M-$7.31M-$7.46M-$6.33M-$5.33M-$6.25M-$4.15M-$4.43M-$4.17M-$6.62M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $31.63M were 99.7% of total assets of $31.71M, against total liabilities of $13.30M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$31.71M$18.61M$19.18M$20.41M$6.66M$6.66M
    Current assets$31.71M$18.61M$19.18M$20.41M$5.83M$5.83M
    Cash and equivalents$31.63M$18.53M$19.13M$19.99M$5.74M$5.74M
    Total liabilities$13.30M$8.89M$6.98M$6.19M$2.42M$10.00K
    Shareholder equity$18.41M$9.71M$12.20M$14.22M-$11.01M-$10.00K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$140.84M$22.38M$25.40M$31.71M$35.59M$27.01M$30.15M$18.61M$17.31M$18.30M$19.71M$19.18M
    Total liabilities$14.19M$13.29M$11.18M$13.30M$11.58M$10.13M$9.19M$8.89M$6.32M$5.77M$5.69M$6.98M
    Cash and equivalents$140.71M$22.16M$25.13M$31.63M$35.44M$26.79M$29.86M$18.53M$17.17M$18.12M$19.46M$19.13M
    Shareholder equity$126.65M$9.08M$14.22M$18.41M$24.01M$16.87M$20.95M$9.71M$10.99M$12.53M$14.02M$12.20M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$16.01M-$12.25M-$15.95M-$13.56M-$9.50M$24.00K
    Free cash flow-$16.01M-$12.25M-$15.95M-$13.56M-$9.50M$24.00K
    Share repurchases$2.10M$382.00K$174.00KN/A$0N/A
    Financing cash flow$29.11M$11.65M$15.09M$27.81M$15.25M$15.25M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$25.28M-$4.53M-$6.51M-$3.97M-$4.49M-$3.37M-$4.17M-$2.46M-$2.40M-$3.02M-$4.36M-$3.85M
    Free cash flowN/AN/A-$6.51M-$3.97M-$4.49M-$3.37M-$4.17M-$2.46M-$2.40M-$3.02M-$4.36M-$3.85M
    Last 12 quarters

    Frequently Asked Questions About NVCT

    What is Nuvectis Pharma's annual revenue?

    Nuvectis Pharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Nuvectis Pharma profitable?

    No. Nuvectis Pharma reported net income of -$26.44M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NVCT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$16.01M minus capital expenditures of $0 produced free cash flow of -$16.01M.

    How much debt does Nuvectis Pharma have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $31.63M.